Dr. Michael M. Einstein, M.D.
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- Icahn School of Medicine at Mount Sinai (2003)
- Years since graduation
- 23
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 304
Licensed in Connecticut since 2011, according to the Connecticut Department of Public Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2003Medical school: Icahn School of Medicine at Mount Sinai
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
CT license 49700 (first issued 2011; active) -
Transplant Hepatology Physician
CT license 49700 (first issued 2011; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Hartford Hospital Hartford, CT
- William W Backus Hospital Norwich, CT
- Day Kimball Hospital Putnam, CT
- Windham Community Memorial Hospital Willimantic, CT
Medical groups
- Hartford Hospital (1,044 clinicians)
- Connecticut Gi PLLC (248 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 304
- Services billed
- 510
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 173 | 125 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 145 | 80 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 86 | 85 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 24 | 24 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 23 | 22 |
| Biopsy of large bowel using a flexible endoscope | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tacrolimus Other prescribers in Hartford, CT | 252 |
| Carvedilol Other prescribers in Hartford, CT | 206 |
| Pantoprazole Sodium Other prescribers in Hartford, CT | 183 |
| Ursodiol Other prescribers in Hartford, CT | 148 |
| Spironolactone Other prescribers in Hartford, CT | 137 |
| Furosemide Other prescribers in Hartford, CT | 134 |
| Xifaxan (rifaximin) Other prescribers in Hartford, CT | 133 |
| Lactulose Other prescribers in Hartford, CT | 80 |
| Mycophenolate Mofetil Other prescribers in Hartford, CT | 76 |
| Vemlidy (tenofovir alafenamide) | 66 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 22 companies reported 122 payments worth $28,660 in total to this clinician.
| Gilead Sciences, Inc. | $15,760 |
|---|---|
| Ipsen Biopharmaceuticals, Inc | $7,350 |
| Mirum Pharmaceuticals, Inc. | $3,317 |
| Janssen Biotech, Inc. | $435 |
| Takeda Pharmaceuticals U.S.A., Inc. | $379 |
| Novo Nordisk Inc | $365 |
| Madrigal Pharmaceuticals | $274 |
| Aimmune Therapeutics, Inc. | $172 |
| Compensation for services other than consulting (speaking, faculty) | $16,172 |
|---|---|
| Consulting Fee | $6,310 |
| Food and Beverage | $3,778 |
| Travel and Lodging | $2,301 |
| Education | $99.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc Jun 13, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $6,272 |
| Gilead Sciences, Inc. Mar 13, 2025 | Compensation for services other than consulting (speaking, faculty) Epclusa · HCV Company’s description;3978804;GTF;10784445 | $3,240 |
| Gilead Sciences, Inc. Jul 16, 2025 | Consulting Fee Livdelzi · INFLAM Company’s description;4285396;VEM US;10784445 | $3,230 |
| Mirum Pharmaceuticals, Inc. Sep 17, 2025 | Consulting Fee Livmarli · Alagille syndrome | $3,080 |
| Gilead Sciences, Inc. Jan 21, 2025 | Compensation for services other than consulting (speaking, faculty) Epclusa · HCV Company’s description;4126583;AHM;10784445 | $3,030 |
| Gilead Sciences, Inc. Sep 30, 2025 | Compensation for services other than consulting (speaking, faculty) Epclusa · HCV Company’s description;4180845;AHM;10784445 | $3,030 |
| Ipsen Biopharmaceuticals, Inc Jun 13, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Washington dc, DC · in-kind | $934 |
| Gilead Sciences, Inc. Oct 24, 2025 | Compensation for services other than consulting (speaking, faculty) Epclusa · HCV Company’s description;4249370;GTF;10784445 | $600 |
| Gilead Sciences, Inc. Mar 1, 2025 | Travel and Lodging Epclusa · HCV · travel to Atlanta, GA · in-kind Company’s description;4026789;GTF;10784445 | $464 |
| Gilead Sciences, Inc. Mar 1, 2025 | Travel and Lodging Epclusa · HCV · travel to Atlanta, GA · in-kind Company’s description;4026795;GTF;10784445 | $350 |
All 17 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Gilead Sciences, Inc. Oct 24, 2025 | Compensation for services other than consulting (speaking, faculty) Epclusa · HCV Company’s description;4249370;GTF;10784445 | $600 |
| Gilead Sciences, Inc. Sep 30, 2025 | Compensation for services other than consulting (speaking, faculty) Epclusa · HCV Company’s description;4180845;AHM;10784445 | $3,030 |
| Mirum Pharmaceuticals, Inc. Sep 17, 2025 | Consulting Fee Livmarli · Alagille syndrome | $3,080 |
| Gilead Sciences, Inc. Jul 16, 2025 | Consulting Fee Livdelzi · INFLAM Company’s description;4285396;VEM US;10784445 | $3,230 |
| Gilead Sciences, Inc. Jul 16, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Boston, MA Company’s description;4285181;VEM US;10784445 | $147 |
| Gilead Sciences, Inc. Jul 16, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Boston, MA Company’s description;4285146;VEM US;10784445 | $41.00 |
| Gilead Sciences, Inc. Jul 16, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Boston, MA Company’s description;4285474;VEM US;10784445 | $9.30 |
| Ipsen Biopharmaceuticals, Inc Jun 13, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $6,272 |
| Ipsen Biopharmaceuticals, Inc Jun 13, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Washington dc, DC · in-kind | $934 |
| Janssen Biotech, Inc. May 9, 2025 | Education TREMFYA · Immunology · in-kind | $99.00 |
| Gilead Sciences, Inc. Mar 20, 2025 | Travel and Lodging Epclusa · HCV · travel to Atlanta, GA Company’s description;4026996;GTF;10784445 | $46.00 |
| Gilead Sciences, Inc. Mar 20, 2025 | Travel and Lodging Epclusa · HCV · travel to Atlanta, GA Company’s description;4026998;GTF;10784445 | $25.48 |
| Gilead Sciences, Inc. Mar 13, 2025 | Compensation for services other than consulting (speaking, faculty) Epclusa · HCV Company’s description;3978804;GTF;10784445 | $3,240 |
| Gilead Sciences, Inc. Mar 1, 2025 | Travel and Lodging Epclusa · HCV · travel to Atlanta, GA · in-kind Company’s description;4026789;GTF;10784445 | $464 |
| Gilead Sciences, Inc. Mar 1, 2025 | Travel and Lodging Epclusa · HCV · travel to Atlanta, GA · in-kind Company’s description;4026795;GTF;10784445 | $350 |
| Gilead Sciences, Inc. Mar 1, 2025 | Travel and Lodging Epclusa · HCV · travel to Atlanta, GA · in-kind Company’s description;4027183;GTF;10784445 | $284 |
| Gilead Sciences, Inc. Jan 21, 2025 | Compensation for services other than consulting (speaking, faculty) Epclusa · HCV Company’s description;4126583;AHM;10784445 | $3,030 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.